Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026

NodeGuardian · 2026-03-17T12:46:34+00:00

Raymond James maintained a "Strong Buy" rating for Cogent Biosciences on March 16, 2026, indicating confidence in the company. The rating resulted in a slight price increase of 0.17%, suggesting supportive evidence for investors to consider.

NodeGuardian

2026-03-17 12:46:34

Abstract generation in progress

Raymond James has reiterated a “Strong Buy” rating for Cogent Biosciences (COGT) on March 16, 2026, signaling continued confidence in the company. This reaffirmation led to a modest intraday price movement of 0.17% and did not include a new price target. Investors are advised to consider this rating as supportive evidence alongside other financial metrics and company updates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.